Conception Hospital
Marseille, 13005, France
NCT Number: NCT04372225
With increasing economic pressures to shorten the length of hospital stay, there has been much recent interest in studying risk factors for the development of postoperative hypocalcemia.
The aim of this study was to investigate in patients undergoing total thyroidectomy whether serum calcium and/or PTH levels can predict hypoparathyroidism.
Looking for future studies?
Notify MeAll sexes
Observational
Marseille, 13005, France
Our study consists of analyzing the calcium (mmol/l) and PTH (pmol/l) levels on the first postoperative day. Postoperative treatment with calcium and vitamin D and the length of hospital stay is also taken into consideration.
We also analyze post-operative complications.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
analysis of postoperative calcium and PTH levels
Time frame: one years
For all 477 patients postoperative calcium and PTH levels and treatment with calcium and vitamin D will be analyzed.
Objective is to identify the calcium and PTH thresholds at which the patient after total thyroidectomy can be discharged without risk of hypocalcemia.
Aix Marseille Université
Other
Predicting Risk Factors of Postoperative Hypocalcemia After Total Thyroidectomy: is Safe Discharge Without Supplementation Possible?
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00743782
Autoimmune Diseases, Autoimmune Polyendocrine Syndrome Type 1
Bethesda, Maryland, United States
View Trial DetailsNCT07395388
Benign Multinodular Goiter, Calcium Metabolism Disorders
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT01199614
Calcium Metabolism Disorders, Endocrine System Diseases
New York, United States
View Trial DetailsNCT05043584
Autofluorescence, Calcium Metabolism Disorders
Esbjerg, Denmark
View Trial Details